Skip to main content
Erschienen in: Annals of Surgical Oncology 4/2017

07.11.2016 | Pancreatic Tumors

Pancreatic Duct Involvement in Well-Differentiated Neuroendocrine Tumors is an Independent Poor Prognostic Factor

verfasst von: Yoshihide Nanno, MD, Ippei Matsumoto, MD, PhD, Yoh Zen, MD, PhD, FRCPath, Kyoko Otani, MD, Jun Uemura, MD, Hirochika Toyama, MD, PhD, Sadaki Asari, MD, PhD, Tadahiro Goto, MD, PhD, Tetsuo Ajiki, MD, PhD, Keiichi Okano, MD, PhD, Yasuyuki Suzuki, MD, PhD, Yoshifumi Takeyama, MD, PhD, Takumi Fukumoto, MD, PhD, Yonson Ku, MD, PhD

Erschienen in: Annals of Surgical Oncology | Ausgabe 4/2017

Einloggen, um Zugang zu erhalten

Abstract

Background

The biological behavior of well-differentiated neuroendocrine tumors of the pancreas (PNETs) is difficult to predict. This study was designed to determine whether involvement of the main pancreatic duct (MPD) serves as a poor prognostic factor for PNETs.

Methods

The involvement of the MPD in PNETs was defined as ductal stenosis inside the tumor mass associated with distal MPDs more than twofold larger in diameter than the proximal ducts. We examined the correlation between MPD involvement and other clinicopathological parameters, including nodal metastasis and recurrence-free survival, in 101 patients treated consecutively at three referral centers in Japan. All patients underwent surgical resection.

Results

MPD involvement was observed in 13 of the 101 cases (13%) and was associated with multiple unfavorable clinicopathological features (e.g., larger tumor size, higher histological grade, more frequent nodal metastasis, and higher recurrence rates). Patients with MPD involvement also showed significantly worse recurrence-free survival than did those without ductal involvement (P < 0.001), with a 5 years recurrence-free rate of 41%. On multivariate analysis, MPD involvement was significantly associated with nodal metastasis [odds ratio (OR) 16; 95% confidence interval (CI) 3.8–89; P < 0.001] and recurrence (OR 8.0; 95% CI 1.7–46; P = 0.009). The radiology–pathology correlation revealed that stenosis of the MPD was due to periductal and/or intraductal tumor invasion. Cases with MPD involvement had microscopic venous invasion (P = 0.010) and perineural infiltration (P = 0.002) more frequently than did those with no ductal infiltration.

Conclusions

MPD involvement in PNETs may serve as an imaging sign indicating an aggressive clinical course.
Literatur
1.
Zurück zum Zitat Oberg K, Eriksson B. Endocrine tumours of the pancreas. Best Pract Res Clin Gastroenterol. 2005;19:753–81.CrossRefPubMed Oberg K, Eriksson B. Endocrine tumours of the pancreas. Best Pract Res Clin Gastroenterol. 2005;19:753–81.CrossRefPubMed
2.
Zurück zum Zitat Postlewait LM, Ethun CG, Baptiste GG, et al. Pancreatic neuroendocrine tumors: Preoperative factors that predict lymph node metastases to guide operative strategy. J Surg Oncol. 2016;114:440–5.CrossRefPubMed Postlewait LM, Ethun CG, Baptiste GG, et al. Pancreatic neuroendocrine tumors: Preoperative factors that predict lymph node metastases to guide operative strategy. J Surg Oncol. 2016;114:440–5.CrossRefPubMed
3.
Zurück zum Zitat Yao JC, Hassan M, Phan A, et al. One hundred years after “carcinoid”: epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J Clin Oncol. 2008;26:3063–72.CrossRefPubMed Yao JC, Hassan M, Phan A, et al. One hundred years after “carcinoid”: epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J Clin Oncol. 2008;26:3063–72.CrossRefPubMed
4.
Zurück zum Zitat Hashim YM, Trinkaus KM, Linehan DC, Strasberg SS, Fields RC, Cao D, Hawkins WG. Regional lymphadenectomy is indicated in the surgical treatment of pancreatic neuroendocrine tumors (PNETs). Ann Surg. 2014;259:197–203.CrossRefPubMedPubMedCentral Hashim YM, Trinkaus KM, Linehan DC, Strasberg SS, Fields RC, Cao D, Hawkins WG. Regional lymphadenectomy is indicated in the surgical treatment of pancreatic neuroendocrine tumors (PNETs). Ann Surg. 2014;259:197–203.CrossRefPubMedPubMedCentral
5.
Zurück zum Zitat Fesinmeyer MD, Austin MA, Li CI, De Roos AJ, Bowen DJ. Differences in survival by histologic type of pancreatic cancer. Cancer Epidemiol Biomark Prev. 2005;14:1766–73.CrossRef Fesinmeyer MD, Austin MA, Li CI, De Roos AJ, Bowen DJ. Differences in survival by histologic type of pancreatic cancer. Cancer Epidemiol Biomark Prev. 2005;14:1766–73.CrossRef
7.
Zurück zum Zitat Krampitz GW, Norton JA, Poultsides GA, Visser BC, Sun L, Jensen RT. Lymph nodes and survival in pancreatic neuroendocrine tumors. Arch Surg. 2012;147:820–7.CrossRefPubMedPubMedCentral Krampitz GW, Norton JA, Poultsides GA, Visser BC, Sun L, Jensen RT. Lymph nodes and survival in pancreatic neuroendocrine tumors. Arch Surg. 2012;147:820–7.CrossRefPubMedPubMedCentral
8.
Zurück zum Zitat Gibril F, Doppman JL, Reynolds JC, et al. Bone metastasis in patients with gastrinomas: a prospective study of bone scanning, somatostatin receptor scanning, and magnetic resonance image in their detection, frequency, location, and effect to their detection on management. J Clin Oncol. 1998;16:1040–53.CrossRefPubMed Gibril F, Doppman JL, Reynolds JC, et al. Bone metastasis in patients with gastrinomas: a prospective study of bone scanning, somatostatin receptor scanning, and magnetic resonance image in their detection, frequency, location, and effect to their detection on management. J Clin Oncol. 1998;16:1040–53.CrossRefPubMed
9.
Zurück zum Zitat Kulke MH, Shah MH, Benson AB 3rd, et al. Neuroendocrine tumors, version 1.2015. J Natl Compr Cancer Netw. 2015;13:78–108. Kulke MH, Shah MH, Benson AB 3rd, et al. Neuroendocrine tumors, version 1.2015. J Natl Compr Cancer Netw. 2015;13:78–108.
10.
Zurück zum Zitat Fesinmeyer MD, Austin MA, Li CI, De Roos AJ, Bowen DJ. Differences in survival by histologic type of pancreatic cancer. Cancer Epidemiol Biomark Prev. 2005;14:1766–73.CrossRef Fesinmeyer MD, Austin MA, Li CI, De Roos AJ, Bowen DJ. Differences in survival by histologic type of pancreatic cancer. Cancer Epidemiol Biomark Prev. 2005;14:1766–73.CrossRef
11.
Zurück zum Zitat Tatsumoto S, Kodama Y, Sakurai Y, Shinohara T, Katanuma A, Maguchi H. Pancreatic neuroendocrine neoplasm: correlation between computed tomography enhancement patterns and prognostic factors of surgical and endoscopic ultrasound-guided fine-needle aspiration biopsy specimens. Abdom Imaging. 2013;38:358–66.CrossRefPubMed Tatsumoto S, Kodama Y, Sakurai Y, Shinohara T, Katanuma A, Maguchi H. Pancreatic neuroendocrine neoplasm: correlation between computed tomography enhancement patterns and prognostic factors of surgical and endoscopic ultrasound-guided fine-needle aspiration biopsy specimens. Abdom Imaging. 2013;38:358–66.CrossRefPubMed
12.
Zurück zum Zitat Tsutsumi K, Ohtsuka T, Mori Y, et al. Analysis of lymph node metastasis in pancreatic neuroendocrine tumors (PNETs) based on the tumor size and hormonal production. J Gastroenterol. 2012;47:678–85.CrossRefPubMed Tsutsumi K, Ohtsuka T, Mori Y, et al. Analysis of lymph node metastasis in pancreatic neuroendocrine tumors (PNETs) based on the tumor size and hormonal production. J Gastroenterol. 2012;47:678–85.CrossRefPubMed
13.
Zurück zum Zitat Shanahan MA, Salem A, Fisher A, Cho CS, Leverson G, Winslow ER, Weber SM. Chromogranin A predicts survival for resected pancreatic neuroendocrine tumors. J Surg Res. 2016;201:38–43.CrossRefPubMed Shanahan MA, Salem A, Fisher A, Cho CS, Leverson G, Winslow ER, Weber SM. Chromogranin A predicts survival for resected pancreatic neuroendocrine tumors. J Surg Res. 2016;201:38–43.CrossRefPubMed
14.
Zurück zum Zitat Obara T, Shudo R, Fujii T, et al. Pancreatic duct obstruction caused by malignant islet cell tumors of the pancreas. Gastrointest Endosc. 2000;51:604–7.CrossRefPubMed Obara T, Shudo R, Fujii T, et al. Pancreatic duct obstruction caused by malignant islet cell tumors of the pancreas. Gastrointest Endosc. 2000;51:604–7.CrossRefPubMed
15.
Zurück zum Zitat Kitami CE, Shimizu T, Sato O, et al. Malignant islet cell tumor projecting into the main pancreatic duct. J Hepatobiliary Pancreat Surg. 2000;7:529–33.CrossRefPubMed Kitami CE, Shimizu T, Sato O, et al. Malignant islet cell tumor projecting into the main pancreatic duct. J Hepatobiliary Pancreat Surg. 2000;7:529–33.CrossRefPubMed
16.
Zurück zum Zitat Akatsu T, Wakabayashi G, Aiura K, et al. Intraductal growth of a nonfunctioning endocrine tumor of the pancreas. J Gastroenterol. 2004;39:584–8.PubMed Akatsu T, Wakabayashi G, Aiura K, et al. Intraductal growth of a nonfunctioning endocrine tumor of the pancreas. J Gastroenterol. 2004;39:584–8.PubMed
18.
Zurück zum Zitat Bosman FT, Cameiro F, Hruban RH, et al. WHO classification of tumours. No. 3. WHO classification of tumours of the digestive system, 4th edn. Lyon: IARC, 2010. Bosman FT, Cameiro F, Hruban RH, et al. WHO classification of tumours. No. 3. WHO classification of tumours of the digestive system, 4th edn. Lyon: IARC, 2010.
19.
Zurück zum Zitat Nanno Y, Toyama H, Otani K, et al. Microscopic venous invasion in patients with pancreatic neuroendocrine tumor as a potential predictor of postoperative recurrence. Pancreatology. 2016;16:882–7.CrossRefPubMed Nanno Y, Toyama H, Otani K, et al. Microscopic venous invasion in patients with pancreatic neuroendocrine tumor as a potential predictor of postoperative recurrence. Pancreatology. 2016;16:882–7.CrossRefPubMed
20.
Zurück zum Zitat Parekh JR, Wang SC, Bergsland EK, Venook AP, Warren RS, Kim GE, Nakakura EK. Lymph node sampling rates and predictors of nodal metastasis in pancreatic neuroendocrine tumor resections: the UCSF experience with 149 patients. Pancreas. 2012;41:840–4.CrossRefPubMed Parekh JR, Wang SC, Bergsland EK, Venook AP, Warren RS, Kim GE, Nakakura EK. Lymph node sampling rates and predictors of nodal metastasis in pancreatic neuroendocrine tumor resections: the UCSF experience with 149 patients. Pancreas. 2012;41:840–4.CrossRefPubMed
21.
Zurück zum Zitat Bilimoria KY, Talamonti MS, Tomlinson JS, Stewart AK, Winchester DP, Ko CY, Bentrem DJ. Prognostic score predicting survival after resection of pancreatic neuroendocrine tumors: analysis of 3851 patients. Ann Surg. 2008;247:490–500.CrossRefPubMed Bilimoria KY, Talamonti MS, Tomlinson JS, Stewart AK, Winchester DP, Ko CY, Bentrem DJ. Prognostic score predicting survival after resection of pancreatic neuroendocrine tumors: analysis of 3851 patients. Ann Surg. 2008;247:490–500.CrossRefPubMed
22.
Zurück zum Zitat Jarufe NP, Coldham C, Orug T, Mayer AD, Mirza DF, Buckels JA, Bramhall SR. Neuroendocrine tumours of the pancreas: predictors of survival after surgical treatment. Dig Surg. 2005;22:157–62.CrossRefPubMed Jarufe NP, Coldham C, Orug T, Mayer AD, Mirza DF, Buckels JA, Bramhall SR. Neuroendocrine tumours of the pancreas: predictors of survival after surgical treatment. Dig Surg. 2005;22:157–62.CrossRefPubMed
23.
Zurück zum Zitat Nagai E, Yamaguchi K, Hashimoto H, Sakurai T. Carcinoid tumor of the pancreas with obstructive pancreatitis. Am J Gastroenterol. 1992;87:361–4.PubMed Nagai E, Yamaguchi K, Hashimoto H, Sakurai T. Carcinoid tumor of the pancreas with obstructive pancreatitis. Am J Gastroenterol. 1992;87:361–4.PubMed
24.
Zurück zum Zitat Ogawa M, Kawaguchi Y, Maruno A, et al. Small serotonin-positive pancreatic endocrine tumors caused obstruction of the main pancreatic duct. World J Gastroenterol. 2012;18:6669–73.CrossRefPubMedPubMedCentral Ogawa M, Kawaguchi Y, Maruno A, et al. Small serotonin-positive pancreatic endocrine tumors caused obstruction of the main pancreatic duct. World J Gastroenterol. 2012;18:6669–73.CrossRefPubMedPubMedCentral
25.
Zurück zum Zitat Chaudhry A, Funa K, Oberg K. Expression of growth factor peptides and their receptors in neuroendocrine tumors of the digestive system. Acta Oncol. 1993;32:107–14.CrossRefPubMed Chaudhry A, Funa K, Oberg K. Expression of growth factor peptides and their receptors in neuroendocrine tumors of the digestive system. Acta Oncol. 1993;32:107–14.CrossRefPubMed
26.
Zurück zum Zitat Chaudhry A, Papanicolaou V, Oberg K, Heldin CH, Funa K. Expression of platelet-derived growth factor and its receptors in neuroendocrine tumors of the digestive system. Cancer Res. 1992;52:1006–12.PubMed Chaudhry A, Papanicolaou V, Oberg K, Heldin CH, Funa K. Expression of platelet-derived growth factor and its receptors in neuroendocrine tumors of the digestive system. Cancer Res. 1992;52:1006–12.PubMed
27.
Zurück zum Zitat Curran T, Pockaj BA, Gray RJ, Halfdanarson TR, Wasif N. Importance of lymph node involvement in pancreatic neuroendocrine tumors: impact on survival and implications for surgical resection. J Gastrointest Surg. 2015;19:152–60.CrossRefPubMed Curran T, Pockaj BA, Gray RJ, Halfdanarson TR, Wasif N. Importance of lymph node involvement in pancreatic neuroendocrine tumors: impact on survival and implications for surgical resection. J Gastrointest Surg. 2015;19:152–60.CrossRefPubMed
28.
Zurück zum Zitat Kaltenborn A, Matzke S, Kleine M, et al. Prediction of survival and tumor recurrence in patients undergoing surgery for pancreatic neuroendocrine neoplasms. J Surg Oncol. 2016;113:194–202.CrossRefPubMed Kaltenborn A, Matzke S, Kleine M, et al. Prediction of survival and tumor recurrence in patients undergoing surgery for pancreatic neuroendocrine neoplasms. J Surg Oncol. 2016;113:194–202.CrossRefPubMed
Metadaten
Titel
Pancreatic Duct Involvement in Well-Differentiated Neuroendocrine Tumors is an Independent Poor Prognostic Factor
verfasst von
Yoshihide Nanno, MD
Ippei Matsumoto, MD, PhD
Yoh Zen, MD, PhD, FRCPath
Kyoko Otani, MD
Jun Uemura, MD
Hirochika Toyama, MD, PhD
Sadaki Asari, MD, PhD
Tadahiro Goto, MD, PhD
Tetsuo Ajiki, MD, PhD
Keiichi Okano, MD, PhD
Yasuyuki Suzuki, MD, PhD
Yoshifumi Takeyama, MD, PhD
Takumi Fukumoto, MD, PhD
Yonson Ku, MD, PhD
Publikationsdatum
07.11.2016
Verlag
Springer International Publishing
Erschienen in
Annals of Surgical Oncology / Ausgabe 4/2017
Print ISSN: 1068-9265
Elektronische ISSN: 1534-4681
DOI
https://doi.org/10.1245/s10434-016-5663-8

Weitere Artikel der Ausgabe 4/2017

Annals of Surgical Oncology 4/2017 Zur Ausgabe

Mehr Frauen im OP – weniger postoperative Komplikationen

21.05.2024 Allgemeine Chirurgie Nachrichten

Ein Frauenanteil von mindestens einem Drittel im ärztlichen Op.-Team war in einer großen retrospektiven Studie aus Kanada mit einer signifikanten Reduktion der postoperativen Morbidität assoziiert.

„Übersichtlicher Wegweiser“: Lauterbachs umstrittener Klinik-Atlas ist online

17.05.2024 Klinik aktuell Nachrichten

Sie sei „ethisch geboten“, meint Gesundheitsminister Karl Lauterbach: mehr Transparenz über die Qualität von Klinikbehandlungen. Um sie abzubilden, lässt er gegen den Widerstand vieler Länder einen virtuellen Klinik-Atlas freischalten.

Was nützt die Kraniektomie bei schwerer tiefer Hirnblutung?

17.05.2024 Hirnblutung Nachrichten

Eine Studie zum Nutzen der druckentlastenden Kraniektomie nach schwerer tiefer supratentorieller Hirnblutung deutet einen Nutzen der Operation an. Für überlebende Patienten ist das dennoch nur eine bedingt gute Nachricht.

Klinikreform soll zehntausende Menschenleben retten

15.05.2024 Klinik aktuell Nachrichten

Gesundheitsminister Lauterbach hat die vom Bundeskabinett beschlossene Klinikreform verteidigt. Kritik an den Plänen kommt vom Marburger Bund. Und in den Ländern wird über den Gang zum Vermittlungsausschuss spekuliert.

Update Chirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

S3-Leitlinie „Diagnostik und Therapie des Karpaltunnelsyndroms“

Karpaltunnelsyndrom BDC Leitlinien Webinare
CME: 2 Punkte

Das Karpaltunnelsyndrom ist die häufigste Kompressionsneuropathie peripherer Nerven. Obwohl die Anamnese mit dem nächtlichen Einschlafen der Hand (Brachialgia parästhetica nocturna) sehr typisch ist, ist eine klinisch-neurologische Untersuchung und Elektroneurografie in manchen Fällen auch eine Neurosonografie erforderlich. Im Anfangsstadium sind konservative Maßnahmen (Handgelenksschiene, Ergotherapie) empfehlenswert. Bei nicht Ansprechen der konservativen Therapie oder Auftreten von neurologischen Ausfällen ist eine Dekompression des N. medianus am Karpaltunnel indiziert.

Prof. Dr. med. Gregor Antoniadis
Berufsverband der Deutschen Chirurgie e.V.

S2e-Leitlinie „Distale Radiusfraktur“

Radiusfraktur BDC Leitlinien Webinare
CME: 2 Punkte

Das Webinar beschäftigt sich mit Fragen und Antworten zu Diagnostik und Klassifikation sowie Möglichkeiten des Ausschlusses von Zusatzverletzungen. Die Referenten erläutern, welche Frakturen konservativ behandelt werden können und wie. Das Webinar beantwortet die Frage nach aktuellen operativen Therapiekonzepten: Welcher Zugang, welches Osteosynthesematerial? Auf was muss bei der Nachbehandlung der distalen Radiusfraktur geachtet werden?

PD Dr. med. Oliver Pieske
Dr. med. Benjamin Meyknecht
Berufsverband der Deutschen Chirurgie e.V.

S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“

Appendizitis BDC Leitlinien Webinare
CME: 2 Punkte

Inhalte des Webinars zur S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“ sind die Darstellung des Projektes und des Erstellungswegs zur S1-Leitlinie, die Erläuterung der klinischen Relevanz der Klassifikation EAES 2015, die wissenschaftliche Begründung der wichtigsten Empfehlungen und die Darstellung stadiengerechter Therapieoptionen.

Dr. med. Mihailo Andric
Berufsverband der Deutschen Chirurgie e.V.